Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardinal spins off medical technology business

Executive Summary

Cardinal Health will spin off its medical technology businesses as a separate public company, leaving Cardinal with its pharmaceutical and medical product distribution business. Cardinal CEO Kerry Clark will retire from the company after completion of the spinoff, to be succeeded by current health care supply chain services CEO George Barrett. David Schlotterbeck, CEO of clinical and medical products, will head the new company, to be headquartered in San Diego. The proposed tax-free spinoff will be done through a pro rata distribution to Cardinal shareholders and is expected to be completed in mid-2009. Cardinal discussed the potential benefits of a spinoff during its most recent quarterly earnings call (1"The Pink Sheet," Aug. 11, 2008, p. 22)

You may also be interested in...



ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva

The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.

FDA Sets New Restrictions For Authorized N95 Decontamination Systems

After reviewing real-world data, the US agency says the decontamination systems should only be used for compatible facemasks and should not be used to clean a mask more than four times.

Biden Signs COVID-19 Relief EO To Expand And Accelerate Testing, Fill PPE Shortages

Under an extensive COVID-19 plan and executive order signed on 21 January, the US president explained how he’ll beef up testing and manufacturing of medtech to fight the virus.

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel